VTVT vTv Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1641489 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $36.84M | $0 | $0 | $0 | $0 | $17,000 |
| R&D expense | $7.53M | $8.77M | $8.98M | $3.91M | $7.02M | $4.10M | $2.83M | $2.23M |
| SG&A expense | $4.89M | $5.16M | $4.60M | $3.98M | $3.68M | $3.62M | $3.67M | $2.67M |
| Operating income | -$12.43M | -$13.93M | $23.26M | -$7.88M | -$10.70M | -$7.72M | -$6.50M | -$4.89M |
| Pretax income | -$11.62M | -$13.05M | $24.13M | -$7.14M | -$10.35M | -$7.38M | -$6.22M | -$4.44M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$11.62M | -$13.05M | $24.13M | -$7.14M | -$8.70M | -$6.05M | -$5.09M | -$3.63M |
| EBITDA | -$12.43M | -$13.93M | $23.26M | -$7.88M | -$10.70M | -$7.72M | -$6.49M | -$4.87M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $77.16M | $86.64M | $98.09M | $88.93M | $98.50M | $25.92M | $31.06M | $36.75M |
| Receivables | — | — | — | — | — | — | — | $62,000 |
| Current assets | $78.60M | $87.59M | $98.81M | $89.89M | $99.46M | $26.37M | $31.92M | $38.11M |
| PP&E, net | — | — | — | — | $14,000 | $16,000 | $19,000 | $28,000 |
| Total assets | $78.61M | $87.59M | $98.81M | $89.90M | $99.49M | $26.45M | $32.03M | $38.27M |
| Current liabilities | $7.02M | $7.02M | $6.88M | $6.64M | $10.16M | $5.29M | $4.32M | $5.20M |
| Total liabilities | $8.92M | $8.96M | $8.85M | $25.46M | $28.95M | $24.04M | $23.13M | $23.96M |
| Shareholders' equity | $69.69M | $78.63M | $89.96M | $64.44M | $70.54M | $2.76M | $7.92M | $12.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.19M | -$11.44M | $9.15M | -$9.25M | -$5.22M | -$5.09M | -$5.69M | -$4.83M |
| Financing cash flow | $709,000 | — | — | -$321,000 | $77.80M | -$42,000 | $0 | $0 |
| Depreciation & amortization | $1,000 | $1,000 | $1,000 | $2,000 | $2,000 | $3,000 | $9,000 | $22,000 |
| Stock-based compensation | $1.97M | $1.73M | $1.39M | $1.02M | $1.01M | $930,000 | $813,000 | $825,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.